This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Korea Institute of Oriental Medicine. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Young-Sil Lee: Innovator in Hyperuricemia Treatment
Introduction
Young-Sil Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of medicine, particularly in the treatment of hyperuricemia and related metabolic disorders. His innovative approach focuses on utilizing natural extracts to address these health issues effectively.
Latest Patents
Young-Sil Lee holds a patent for a composition aimed at preventing, ameliorating, or treating hyperuricemia. The patent describes a formulation that includes an extract as an effective ingredient. This composition has shown promise in reducing uric acid levels in animal models. The natural origin of the extract makes it a viable option for industries dealing with hyperuricemia and related metabolic disorders. It is particularly effective for the prevention and treatment of gout and gouty arthritis.
Career Highlights
Young-Sil Lee is affiliated with the Korea Institute of Oriental Medicine. His work there has allowed him to explore the therapeutic potential of traditional medicine in modern applications. His research has led to advancements in understanding how natural products can be utilized in treating chronic conditions.
Collaborations
Young-Sil Lee has collaborated with notable colleagues, including Dong Seon Kim and Ohn Soon Kim. These partnerships have fostered a collaborative environment that enhances research and innovation in their field.
Conclusion
Young-Sil Lee's contributions to the treatment of hyperuricemia highlight the importance of integrating traditional knowledge with modern scientific approaches. His work continues to pave the way for new therapeutic options in managing metabolic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
